This trial is to study the long-term effects of the drug brolucizumab on patients with neovascular age-related macular degeneration. The study will last for 56 weeks and will follow patients who have already completed the CRTH258A2303 study.
- Age-Related Macular Degeneration (AMD)
2 Primary · 7 Secondary · Reporting Duration: Baseline, 52 and 56 weeks
Awards & Highlights
1 Treatment Group
brolucizumab 6 mg
1 of 1
255 Total Participants · 1 Treatment Group
Primary Treatment: brolucizumab · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
|Novartis Investigative Site||100.0%|
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Novartis Investigative Site: < 48 hours
Frequently Asked Questions
Has brolucizumab acquired approval from the Food and Drug Administration?
"Brolucizumab's safety is supported by Phase 4 trial data, thus receiving the highest score of 3." - Anonymous Online Contributor
Are there any remaining openings for individuals to participate in this clinical trial?
"This experiment is currently recruiting candidates, with the initial posting dating back to December 16th 2020. The details have been updated as recently as September 15th 2022 on clinicaltrials.gov." - Anonymous Online Contributor
Has brolucizumab been previously tested in other controlled experiments?
"Currently, 10 medical studies involving brolucizumab are active, 5 of which have reached Phase 3. Notably, Porto and Cataluna each host a trial for this drug while there are 360 other locations all over the world running trials as well." - Anonymous Online Contributor
What is the aggregate enrollment figure for this clinical trial?
"Indeed, data found on clinicaltrials.gov clearly states that this medical experiment is currently open for enrolment. The trial was initially announced on December 16th 2020 and the most recent update can be dated back to September 15th 2022. A total of 255 participants are required from one single testing site." - Anonymous Online Contributor
What is the primary aim of this experiment?
"This trial will evaluate brolucizumab's efficacy over a Baseline, 52 and 56 week duration. Primary outcomes of the study include anatomical changes in intraretinal fluid and/or subretinal fluid, as well as alterations to visual acuity. Secondary objectives focus on assessing ocular and non-ocular Adverse Events (AEs) up to Week 56." - Anonymous Online Contributor
Does this clinical trial mark a new milestone in its field of research?
"Novartis Pharmaceuticals initially sponsored the first research of brolucizumab in 2019, which involved 263 patients. After successful Phase 3 drug approval following that study, there are now 10 active trials for this medication across 146 cities and 29 countries." - Anonymous Online Contributor